|Treatment Guidelines and the Interface with Prevention|
|Paul Volberding, MD, Vice Chair of the Department of Medicine at UCSF, Director of CFAR, and Chief of Medical Services at the San Francisco VA Medical Center|
Dr. Volberding discusses the recent shifts in U.S. HIV treatment guidelines, especially regarding early initiation of ART, and reviews data on efficacy of ARVs in preventing sexual transmission of HIV. He discusses both ART for HIV-infected persons and preexposure prophylaxis for uninfected persons.
| Presenter: Paul A. Volberding, MD|
Dr. Volberding is a professor and vice chair of the Department of Medicine and director of the Center for AIDS Research at the University of California, San Francisco (UCSF), and Chief of Medical Services at the San Francisco Veterans Affairs Medical Center. Dr. Volberding’s professional activities centered for more than 20 years at SFGH, where he established a model program of AIDS patient care, research, and professional education. His research career began with investigations of HIV-related malignancies, especially Kaposi's sarcoma. His primary research focus, however, shifted to clinical trials of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection and for continuous service on the two major guidelines panels for antiretroviral therapy.